Harmony Biosciences Holdings (HRMY) Debt to Equity (2019 - 2025)
Harmony Biosciences Holdings (HRMY) has disclosed Debt to Equity for 7 consecutive years, with $0.19 as the latest value for Q4 2025.
- Quarterly Debt to Equity fell 30.85% to $0.19 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.19 through Dec 2025, down 30.85% year-over-year, with the annual reading at $0.19 for FY2025, 30.85% down from the prior year.
- Debt to Equity hit $0.19 in Q4 2025 for Harmony Biosciences Holdings, down from $0.2 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.81 in Q1 2021 to a low of $0.19 in Q4 2025.
- Historically, Debt to Equity has averaged $0.61 across 5 years, with a median of $0.41 in 2023.
- Biggest five-year swings in Debt to Equity: plummeted 55.87% in 2022 and later decreased 12.3% in 2024.
- Year by year, Debt to Equity stood at $1.03 in 2021, then plummeted by 53.78% to $0.48 in 2022, then decreased by 12.87% to $0.41 in 2023, then tumbled by 34.39% to $0.27 in 2024, then tumbled by 30.85% to $0.19 in 2025.
- Business Quant data shows Debt to Equity for HRMY at $0.19 in Q4 2025, $0.2 in Q3 2025, and $0.22 in Q2 2025.